Bangladesh, a country that was previously known for natural resource-based sectors like textiles in the business world, has now emerged as one of the fastest growing pharmaceutical-exporting nations. After tobacco, the pharmaceutical sector is the second largest revenue generating industry in Bangladesh, and the country looks set to emerge as a respected source of quality medicines.
The million-dollar industry is continuously expanding, rising to new heights with new and improved products, and
Apex Pharma Ltd (
APL) is fast becoming a shining star in the Bangladeshi pharma sector.
This year has been particularly significant for APL for several reasons, most notably that it signed a deal with Sanofi-Aventis, a global pharmaceutical giant, to market, promote and distribute selected Sanofi-Aventis’ products. Sanofi-Aventis, based in France, is the number one pharmaceutical multinational in Bangladesh. Mr AM Faruque, Managing Director and Chief Executive Officer of APL, said: “I am very delighted with this ground breaking agreement which will take advantage of both companies’ strengths to deliver high quality medicines to the maximum number of doctors, chemists & patients.”
Iftekharul Islam, Managing Director of Sanofi-aventis Bangladesh Limited, added: “Through this agreement we are appointing Apex Pharma as the distributor for our five selected products and we believe their broad coverage will be a useful addition for the purpose of offering quality medicines to a maximum number of doctors, pharmacies and patients.”
This year, APL also created history in the Bangladesh pharma industry by introducing the first-ever team of professional graduate pharmacists as “Medico-Marketing Executives”.
The aim of this unique initiative is to enhance the quality of pharmaceutical company medicinal communication and services to the medical profession. It will bring a new dimension to the relationship between pharmaceutical manufacturers and the medical community that will provide a tangible benefit to the healthcare system by encouraging best use of APL’s range of products.
This initiative is comprised of more than 100 fully trained pharmacists in the first phase. Importantly, it also creates a new career path for pharmacists in Bangladesh. “Apex is coming on in a big way,” said Mr Faruque.
Another milestone for APL this year was the signing of a comprehensive contract with Rob Walker GMP Consultancy Ltd (RWGMP) to obtain UK MHRA and Australian TGA accreditations for its purpose-built manufacturing facility. RWGMP is based in the UK and has vast experience in obtaining MHRA accreditations in Europe, Africa and Asia.
APL is moving fast towards attaining its operational vision of becoming a global centre of excellence for pharmaceutical manufacturing. The company intends to continue partnering with multinational companies to ensure access to the latest manufacturing technologies and newest products.
Apex Pharma look set to achieve its vision to become one of the top ten pharmaceutical manufacturers in Bangladesh within the shortest possible time.
0 COMMENTS